Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

12536

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Melanoma, Cutaneous Malignant, Mucosal Melanoma
Interventions: IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel; Biological · Drug
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more

Conditions: Asthma
Interventions: tilrekimig, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Bakersfield, California • Miami, Florida • White Marsh, Maryland + 10 more

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ublituximab; Biological
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 19
States / cities: Pasadena, California • Denver, Colorado • Miami, Florida + 16 more

Conditions: Trauma, Hemorrhage
Interventions: Calcium Gluconate, Vasopressin, saline placebo; Drug
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 13 more

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions: PF-06821497, Docetaxel, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 70
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 49 more

Conditions: Parkinson's Disease (PD), Deep Brain Stimulation
Interventions: buntanetap/posiphen; Drug
Lead sponsor: Annovis Bio Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 29
States / cities: Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 25 more

Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab, Venetoclax, Zanubrutinib; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 150
States / cities: Tucson, Arizona • Irvine, California • Coral Gables, Florida + 113 more

Conditions: Viral Lung Infection and Acute Respiratory Failure
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more

Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions: Adagrasib, Pembrolizumab; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 220
States / cities: Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more

Conditions: Solid Tumors
Interventions: INCB161734, Placebo, Investigator's choice of chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 69
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 55 more

Conditions: Schizophrenia
Interventions: Xanomeline/Trospium Chloride, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 32
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Endometrial Neoplasms, Endometrial Cancer
Interventions: PF-08634404, Pembrolizumab, Standard of Care Chemotherapy; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 42
States / cities: Jupiter, Florida • Orlando, Florida • Coon Rapids, Minnesota + 31 more

Clinical trials in Miami, Florida

Filter and sort this location

Live official records

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

A Study of Buntanetap in Participants With PD

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer